This study will be a randomized, double-blind, placebo-controlled 3-arm parallel study with a nested crossover design for positive control with moxifloxacin administration in healthy male and female participants.~Participants will be randomized to receive treatment with either cotadutide during the 13-week treatment period (Arm 1) or cotadutide-placebo (Arm 2).~The cotadutide-placebo treatment arm will be further divided into 2 subgroups (Arms 2A and 2B), in a nested crossover design for only the placebo-treated participants.~Participants will be randomized in a 2:1:1 ratio to Arm 1, Arm 2A, and Arm 2B.~Approximately 80 participants will be randomized to have 64 evaluable participants in the study.~Each participant will be involved in the study for approximately 22 weeks.
This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.